Lars Fruergaard Jørgensen
Lars Fruergaard Jørgensen is the CEO of Novo Nordisk, a leading global healthcare company based in Denmark that specializes in diabetes care and hormone replacement therapies. Under his leadership, the company has focused on innovation and sustainability, driving advancements in diabetes medications and weight management solutions. Recently, he has been vocal about the challenges of high drug prices in the U.S., addressing issues related to pharmacy benefit managers and the pricing mechanisms that affect patient access to medications.
Not in the pool (under ¢1).
Recent news mentions
Mike Doustdar succeeded Lars Fruergaard Jørgensen as CEO earlier this year.
Novo får godkendt salg af Wegovy i pilleform i USA
Denmark· 2025-12-23
Mike Doustdar was appointed chief executive of Novo Nordisk this summer after his predecessor, Lars Fruergaard Jørgensen, was ousted over concerns the company was losing its dominance in the field.
Novo Nordisk shares slide after Ozempic pill fails in Alzheimer’s trials | Pharmaceuticals industry
United Kingdom· 2025-11-25
Lars Fruergaard Jørgensen was fired as CEO of Novo Nordisk due to declining results.
Novo Nordisk har fått kritikk for reklame rettet mot kvinner i overgangsalderen.
Norway· 2025-11-21
Lars Fruergaard Jørgensen was forced out as chief executive of Novo Nordisk in May after a weak earnings report.
Novo Nordisk to cut staff numbers at Irish business – The Irish Times
Ireland· 2025-09-30
Lars Fruergaard Jørgensen was replaced as chief executive of Novo Nordisk in May 2025.
Ozempic-maker Novo Nordisk to cut 9,000 jobsUnited Kingdom· 2025-09-10
Lars Fruergaard Jørgensen was the former CEO of Novo Nordisk who predicted layoffs after a tough period for the company.
Novo Nordisk fyrer tusindvis af medarbejdereDenmark· 2025-09-10Lars Fruergaard Jørgensen expressed in his farewell that layoffs were on the horizon for Novo Nordisk.
»De kommer ikke til at tjene de fantasilioner, man havde stillet i udsigt«.Denmark· 2025-09-10Lars Fruergaard Jørgensen, the former CEO of Novo Nordisk, indicated that layoffs were likely.
Novo Nordisk beder nyansatte om ikke at møde op alligevelDenmark· 2025-08-28Lars Fruergaard Jørgensen was fired by Lars Rebien Sørensen, leading to significant criticism of the latter.
»Han er helt ligeglad med, hvad vi tænker om ham«Denmark· 2025-08-17
Lars Fruergaard Jørgensen was the CEO of Novo Nordisk before being separated from the company.
Vom Börsenstar zum Sorgenkind – findet Novo Nordisk zurück in die Spur?
Switzerland· 2025-08-07
Lars Fruergaard Jørgensen is the chief executive of Novo Nordisk who reported on the sales growth of its GLP-1 brands.
THG says high whey protein prices will a chunk out of profitsUnited Kingdom· 2025-08-06
Lars Fruergaard Jørgensen, the outgoing CEO of Novo Nordisk, indicates that there will likely be layoffs in the company.
»Vi kommer nok ikke uden om fyringer«Denmark· 2025-08-06Lars Fruergaard Jørgensen is the outgoing CEO of Novo Nordisk.
Novo Nordisk fremlægger halvårsregnskabDenmark· 2025-08-06Lars Fruergaard Jørgensen was the former CEO of Novo Nordisk who was named 'Person of the Year' by Financial Times.
Novos krise er en bimlende alarm for de danske politikereDenmark· 2025-08-04The outgoing CEO of Novo Nordisk, Lars Fruergaard Jørgensen, received a letter from President Trump regarding product pricing.
Novos kursfald mindskes efter historie om amerikansk Medicare-dækning af vægttabsmedicinDenmark· 2025-08-02
Lars Fruergaard Jørgensen is the outgoing CEO of Novo Nordisk.
Trump sender brev til Novo NordiskDenmark· 2025-07-31
Lars Fruergaard Jørgensen was removed as CEO of Novo Nordisk for failing to maintain the company's leading position.
Najhodnotnejšia firma Európy ťahala HDP celej krajiny. Prečo zrazu prudko padá?
Slovakia· 2025-07-30
Lars Fruergaard Jørgensen's surprise exit was announced in May.
Wegovy maker Novo Nordisk warns of slower profits as rivals biteUnited Kingdom· 2025-07-29
Lars Fruergaard Jørgensen was removed from his position as CEO of Novo Nordisk earlier in the summer.
Novo Nordisk rasar på börsen efter sänkta prognoser
Sweden· 2025-07-29
Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk.
Novo Nordisk offentliggør stor nedjustering for 2025Denmark· 2025-07-29Lars Fruergaard Jørgensen will step down after eight years as the CEO of Novo Nordisk.
Novo Nordisk udpeger ny topchef midt i aktiestyrtdykDenmark· 2025-07-29Lars Fruergaard Jørgensen was the chief executive of Novo Nordisk for more than three decades before being ousted.
a new set of tariffs, and a company in Kinsale – The Irish TimesIreland· 2025-07-28
Lars Fruergaard Jørgensen was the CEO of Novo Nordisk who saw significant growth in the company before being dismissed.
Danmark har skapt et slankeeventyr. Nå er de i trøbbel.Norway· 2025-07-13Lars Fruergaard Jørgensen was the CEO of Novo Nordisk who saw the company's sales and stock price triple since he took over in 2017.
Danmark har skapt et slankeeventyr. Nå er de i trøbbel.Norway· 2025-07-12Lars Fruergaard Jørgensen made too many mistakes in communication and execution, leading to his dismissal.
«Novo Nordisk wird über die kommenden fünf Jahre gut wachsen»Switzerland· 2025-06-23
Lars Fruergaard Jørgensen will step down as CEO of Novo Nordisk amid market challenges.
Moody’s strips US of AAA credit rating, ASX set to dip
Australia· 2025-05-18
Lars Fruergaard Jørgensen was the director of Novo Nordisk for eight years and had been with the company for 34 years.
»Det er på niveau med en ministerfyring eller måske endda over det«Denmark· 2025-05-17
Lars Fruergaard Jørgensen was the director of Novo Nordisk for eight years and has been with the company for 34 years.
»Det er på niveau med en ministerfyring eller måske endda over det«Denmark· 2025-05-16Lars Fruergaard Jørgensen has led the company since 2017, overseeing its rise to become the most valuable company in Europe after the launch of its flagship anti-obesity drugs.
Wegovy-maker Novo Nordisk abruptly ousts chief executiveUnited Kingdom· 2025-05-16
Lars Fruergaard Jørgensen is stepping down as CEO of Novo Nordisk after a significant decline in the company's value.
Novo Nordisk-direktør stopper efter markant svækkelse af virksomhedens værdiDenmark· 2025-05-16